PAH and TRI collaboration results in world first with successful nerve repair surgery

The first patient of an ongoing clinical trial has recovered well following world-first sutureless nerve repair surgery performed at Princess Alexandra Hospital. 

In conjunction with the Translational Research Institute’s (TRI) Translational Trials Team, and Australian Centre for Complex Integrated Surgical Solutions (ACCISS), the COAPTIUM Connect System Australian trial is currently underway with procedures performed at both PA Hospital and Gold Coast University Hospital. 

PA Hospital Plastic and Reconstructive Surgeon, Dr Michael Wagels who performed the first surgery said the technology allows nerve repair to be made without the use of sutures which can negatively impact the nerve. 

“Removing the need for sutures allows better regeneration of the nerve, benefiting the patient long term,” said Dr Wagels. 

“The coaptation performed in this first surgery was straightforward and the patient has recovered well. I am optimistic this new technology can bring us a step closer to better nerve repair outcomes in the future,” he said. 

The COAPTIUM Connect Sutureless Nerve Coaptation System, by medical technology company TISSIUM, has been designed for consistent nerve repair, leveraging their unique biopolymer platform. 

TISSIUM CEO Christophe Bancel said the technology has the potential to revolutionise the field of tissue reconstruction in multiple therapeutic areas.

“The first clinical use of this system is the culmination of years of research and an important step toward the goal of enabling atraumatic tissue repair,” he said.

“We would like to thank PA Hospital’s Dr Michael Wagels, Gold Coast University Hospital’s Prof Randy Bindra, and their respective staff members for successfully leading this important clinical study.”

TRI CEO Professor Scott Bell said the trial underscored the value of collaboration between clinicians and industry, essential in translating research findings into new treatments to enhance patient outcomes. In this case, providing a novel surgical option for a challenging medical condition. 

“Providing the link through our Translational Trials team, TRI’s support of the clinical trial has been crucial,” said Prof Bell. 

The first patient was enrolled as part of the peripheral nerve repair study in Australia and was announced March 30, 2023. The trial is ongoing.

Photo courtesy: Metro South Health